Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Datascope Stock Rebounds With ProLumen Introduction; OTC Index Up 3%

This article was originally published in The Gray Sheet

Executive Summary

Datascope's U.S. dialysis access market entry with the ProLumen peripheral thrombectomy device March 23 aided a 4.4% stock price gain for the month

You may also be interested in...



Abbott StarClose Opens Vascular Closure Options; U.S. Launch Set For 2005

Abbott believes its StarClose vascular closure device will represent a competitive alternative to St. Jude's market leading AngioSeal upon U.S. approval in 2005

Abbott StarClose Opens Vascular Closure Options; U.S. Launch Set For 2005

Abbott believes its StarClose vascular closure device will represent a competitive alternative to St. Jude's market leading AngioSeal upon U.S. approval in 2005

Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment

Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system

Related Content

UsernamePublicRestriction

Register

MT020040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel